Navigation Links
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
Date:11/3/2008

Company to Host Update Conference Call Today at 8:30 a.m. EST

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the three and nine months ended September 30, 2008.

For the third quarter of 2008, Rigel reported a net loss of $37.7 million, or $1.03 per share, compared to a net loss of $18.9 million, or $0.61 per share, in the third quarter of 2007. Weighted average shares outstanding for the third quarters of 2008 and 2007 were 36.6 million and 31.0 million, respectively.

There were no contract revenues from collaborations reported in the third quarters of 2008 and 2007.

Rigel reported operating expenses of $38.7 million in the third quarter of 2008, compared to $20.4 million in the third quarter of 2007. The increase in operating expenses was primarily due to increases in clinical development expenses and, to a lesser extent, stock-based compensation expense. The increase in clinical development expenses was mainly due to the costs associated with the ongoing Phase 2b clinical trials of R788 in rheumatoid arthritis (TASKi2 and TASKi3). Stock-based compensation expense increased from $2.8 million in the third quarter of 2007 to $6.0 million in the third quarter of 2008, primarily due to the higher valuation of options granted in the first quarter of 2008.

For the nine months ended September 30, 2008, Rigel reported a net loss of $99.0 million, or $2.76 per share, compared to a net loss of $55.3 million, or $1.96 per share, for the same period last year. Rigel recorded no contract revenue from collaborations for the first nine months of 2008, compared with $4.6 million for the same period in 2007.

As of Se
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
3. Rigel to Present at BIO CEO & Investor Conference
4. Rigel Announces Pricing of Public Offering of Common Stock
5. Rigel to Present Research Programs at Scientific Conferences
6. Rigel to Present at BIO Investor Forum 2007
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
9. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
10. Sharps Compliance Corp. Announces Appointment of John R. Grow as President and Chief Operating Officer
11. BMP Sunstone Announces Participation in November Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview with ... session that he will lead on “Stem Cells” at the ... 2015 in London. In the interview posted online ... respond to several questions on the current state of technologies ... toxicity, and future trends in the use of stem cells ...
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... that its three Promissory Note holders, two of whom ... each in July 2014 for a total of $ ... converted into 3,500,001 restricted common shares. Notes were repayable ... Note and the coupon were convertible into common shares ...
(Date:9/29/2014)... Transparency Market Research, in its report ... HPPS, by Application - Cancer, Metabolic, CVS, CNS & ... Delivery) - Global Industry Analysis, Size, Share, Growth, Trends ... peptide therapeutics market was worth US$14.1 billion in 2011 ... at an 8.7% CAGR. , The two main types ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... MILWAUKEEThe growing popularity of digital music recorders, digital ... Brady Corporation 's recent acquisition of ID ... manufacturer and supplier of pressure sensitive die-cut components ... Brady Asia-Pacific Allan Klotsche, this acquisition, along with ...
... In order to surpass its original goal for life-long learning ... (ADL) Co-Laboratory has plans to move from University Research Park ... will make the move Sept. 1, a bit behind ... While delays in the approval processes are to blame for ...
... recently announced it received a Phase I small business ... Cancer Institute . , ,The grant, according to chief executive ... rapidly measure the activity of enzymes that are relevant to ... could develop a way to quickly quantify enzyme activity that ...
Cached Biology Technology:Brady continues growth through Asian acquisition 2Academic ADL Co-Lab moving to downtown Madison 2Academic ADL Co-Lab moving to downtown Madison 3
(Date:9/29/2014)... simple spheres of fluid, not normally considered capable of ... made droplets of alcohol move through water. In the ... able to move on your own to be ... organisms. But also non-living entities can be self-moving, report ... Chemical Technology in Prague, Czech Republic. , The researchers ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... with Multiple Sclerosis (MS) were able to safely tolerate ... to a study published today in the journal ... is the first of its kind, was conducted by ... Celgene Corporation and collaborators at several other institutions. ... early signals in the data also suggested that a ...
Breaking Biology News(10 mins):Scientists make droplets move on their own 2Cells from placentas safe for patients with multiple sclerosis 2
... (Santa Barbara, Calif.) New research at UC Santa Barbara ... develop. The study is part of the campus,s expanding vision ... versions of The Proceedings of the National Academy of ... (IOVS). The scientists document how they used mice ...
... the collaboration of the Spanish Foundation for Biodiversity, the Charter ... the AZTI-Tecnalia R+D Centre will be studying the re-stocking of ... the months of May, June and July, respectively, in three ... gather the information needed to be able to manage the ...
... This release is available in German . ... research in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) ... was taken by the appropriate Grants Committee in Bonn. The ... four and half years, during which time they will receive ...
Cached Biology News:UCSB scientists make strides in vision research 2A study will enable the survival and growth of the 3 development phases of the European eel 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10
NATIVE, ENZYME PORCINE TRYPSIN...
See product name for description....
Mycoplasma tested...
... Cloning Checker Kits provide two highly efficient ... without time-consuming plasmid preparation. By using the ... you need to do is to transfer ... from the transformation plates into the solutions ...
Biology Products: